Risperidone (R64 766) in psychotic patients. A first clinical therapeutic exploration.
Seventeen therapy-resistant adult male psychotic inpatients were treated in an exploratory open study with the new combined serotonin-S2 and dopamine-D2 antagonist risperidone (R 64 766). The mean daily dose was 4.5 mg orally, and the mean duration of treatment 6 months. There were 11 responders, 5 non-responders and 1 drop-out. Risperidone combined an effective antidelusional potency with important contact- and mood-improving properties, while at the same time it reduced existing extrapyramidal symptoms (EPS). Three out of the 5 non-responders were probably underdosed. Risperidone was very well tolerated, reported side effects were mild and transient, and no reason for premature interruption of the therapy.
Roose
K
K
Sint-Jan de Deo Instituut, Gent, Belgie.
Gelders
Y
Y
Heylen
S
S
D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D004341:Drug Evaluation; D006801:Humans; D007555:Isoxazoles / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010080:Oxazoles / Q000627:therapeutic use*; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use*; D011618:Psychotic Disorders / Q000188:drug therapy*; D018967:Risperidone
D014150:Antipsychotic Agents; D007555:Isoxazoles; D010080:Oxazoles; D010880:Piperidines; D018967:Risperidone